# ASTROTECH Corp: overview ASTC · Nasdaq · CIK 1001907 · [Technology](/sectors/technology.md) · fiscal year ends Jun 30 Pages: [Overview](/companies/astc.md) · [Financials](/companies/astc/financials.md) · [Filings](/companies/astc/filings.md) · [Insiders](/companies/astc/insiders.md) Latest reported revenue: [$913.0k](/filings/0001437749-26-031175.md) for Q4 FY2026, three months to 2026-06-30, from the 10-K filed Sep 25, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax, accession 0001437749-26-031175). ## Last eight quarters | Line item | Unit | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [34.0](/filings/0001437749-25-034858.md) | [261](/filings/0001437749-26-003997.md) | [534](/filings/0001437749-26-026366.md) | [1,049](/filings/0001437749-26-031175.md) | [297](/filings/0001437749-25-034858.md) | [148](/filings/0001437749-26-003997.md) | [343](/filings/0001437749-26-026366.md) | [913](/filings/0001437749-26-031175.md) | | Gross margin | % | [26.5%](/filings/0001437749-25-034858.md) | [59.4%](/filings/0001437749-26-003997.md) | [44.4%](/filings/0001437749-26-026366.md) | [7.1% d](/filings/0001437749-26-031175.md) | [63.3%](/filings/0001437749-25-034858.md) | [5.4%](/filings/0001437749-26-003997.md) | [19.5%](/filings/0001437749-26-026366.md) | [(4.9%) d](/filings/0001437749-26-031175.md) | | Operating margin | % | [(10670.6%)](/filings/0001437749-25-034858.md) | [(1655.6%)](/filings/0001437749-26-003997.md) | [(724.2%)](/filings/0001437749-26-026366.md) | [(278.2%) d](/filings/0001437749-26-031175.md) | [(1190.6%)](/filings/0001437749-25-034858.md) | [(2635.8%)](/filings/0001437749-26-003997.md) | [(1006.7%)](/filings/0001437749-26-026366.md) | [(355.8%) d](/filings/0001437749-26-031175.md) | | Net margin | % | [(9641.2%)](/filings/0001437749-26-026366.md) | [(1536.0%)](/filings/0001437749-26-026366.md) | [(680.3%)](/filings/0001437749-26-026366.md) | [(279.3%) d](/filings/0001437749-26-031175.md) | [(1166.7%)](/filings/0001437749-26-026366.md) | [(2653.4%)](/filings/0001437749-26-026366.md) | [(1098.5%)](/filings/0001437749-26-026366.md) | [(357.7%) d](/filings/0001437749-26-031175.md) | | Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Free cash flow | $k | [(3,879)](/filings/0001437749-25-034858.md) | [(3,363) d](/filings/0001437749-26-003997.md) | [(3,888) d](/filings/0001437749-26-026366.md) | [(2,709) d](/filings/0001437749-26-031175.md) | [(4,384)](/filings/0001437749-25-034858.md) | [(3,954) d](/filings/0001437749-26-003997.md) | [(3,688) d](/filings/0001437749-26-026366.md) | [(2,310) d](/filings/0001437749-26-031175.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL not reported. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. ## Last five fiscal years | Line item | Unit | FY2022 (2022-06-30) | FY2023 (2023-06-30) | FY2024 (2024-06-30) | FY2025 (2025-06-30) | FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.9](/filings/0001437749-23-027063.md) | [0.8](/filings/0001437749-24-029650.md) | [1.7](/filings/0001437749-25-029909.md) | [1.0](/filings/0001437749-25-029909.md) | [0.9](/filings/0001437749-26-031175.md) | | Gross margin | % | [22.1%](/filings/0001437749-23-027063.md) | [40.8%](/filings/0001437749-24-029650.md) | [44.2%](/filings/0001437749-25-029909.md) | [47.5%](/filings/0001437749-26-031175.md) | [23.8%](/filings/0001437749-26-031175.md) | | Operating margin | % | [(989.1%)](/filings/0001437749-23-027063.md) | [(1474.7%)](/filings/0001437749-24-029650.md) | [(781.2%)](/filings/0001437749-25-029909.md) | [(1473.4%)](/filings/0001437749-26-031175.md) | [(1548.5%)](/filings/0001437749-26-031175.md) | | Net margin | % | [(958.6%)](/filings/0001437749-23-027063.md) | [(1285.6%)](/filings/0001437749-24-029650.md) | [(686.2%)](/filings/0001437749-25-029909.md) | [(1385.0%)](/filings/0001437749-26-031175.md) | [(1580.2%)](/filings/0001437749-26-031175.md) | | Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | | Free cash flow | $m | [(7.4)](/filings/0001437749-23-027063.md) | [(9.5)](/filings/0001437749-24-029650.md) | [(10.3)](/filings/0001437749-25-029909.md) | [(13.8)](/filings/0001437749-26-031175.md) | [(14.3)](/filings/0001437749-26-031175.md) | - Revenue. XBRL Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Diluted EPS. XBRL not reported. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/astc/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $597.6k | 54,799 | | New +54,799 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $243.8k | 22,356 | | Added +13,151 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $220.2k | 20,188 | | Unchanged | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $169.4k | 15,533 | | Reduced −3,814 | | [J. Safra Sarasin Holding AG](/funds/1890222.md) | 2026-06-30 | $140.0k | 27,300 | | Unchanged | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $120.7k | 11,068 | | New +11,068 | | [SCS Capital Management LLC](/funds/1303159.md) | 2026-06-30 | $120.0k | 11,000 | | Reduced −761 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $86.8k | 7,956 | | Added +3,617 | | [JONES FINANCIAL COMPANIES LLLP](/funds/815917.md) | 2026-06-30 | $8.2k | 886 | | New +886 | | [Tower Research Capital LLC (TRC)](/funds/1533421.md) | 2026-06-30 | $7.3k | 667 | | Reduced −1,593 | ## Recent filings [All 690 filings](/companies/astc/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-23 | 08:21 ET | [DEF 14A](/filings/0001437749-26-033333.md) | Proxy statement, period 2026-12-04 | 0001437749-26-033333 | | 2026-10-19 | 20:25 ET | [8-K](/filings/0001437749-26-032941.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001437749-26-032941 | | 2026-09-25 | 12:26 ET | [10-K](/filings/0001437749-26-031175.md) | Annual report, period 2026-06-30 | 0001437749-26-031175 | | 2026-09-25 | 12:20 ET | [8-K](/filings/0001437749-26-031173.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-26-031173 | | 2026-08-19 | 21:26 ET | [8-K](/filings/0001437749-26-028569.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-028569 | | 2026-08-06 | 21:26 ET | [10-Q/A](/filings/0001437749-26-026366.md) | Quarterly report, amended, period 2026-03-31 | 0001437749-26-026366 | | 2026-07-22 | 12:41 ET | [8-K](/filings/0001437749-26-024046.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001437749-26-024046 | | 2026-06-16 | 12:32 ET | [8-K](/filings/0001437749-26-020737.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-020737 | | 2026-06-03 | 10:01 ET | [8-K](/filings/0001437749-26-019250.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001437749-26-019250 | | 2026-05-13 | 12:30 ET | [10-Q](/filings/0001437749-26-016543.md) | Quarterly report, period 2026-03-31 | 0001437749-26-016543 | ## Latest annual report [Form 10-K for the fiscal year ended Jun 30, 2026](/filings/0001437749-26-031175.md), filed Sep 25, 2026. ## Forecast league Q1 FY2027, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/26612d84-70f3-4c9c-bf03-4ee5a97e7d91) ## About the filer - CIK: 1001907 - Tickers: ASTC - Exchange: Nasdaq - SIC code: 3826 Laboratory Analytical Instruments - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:29 ET. No prices; not investment advice.